
An Update on African AIDS Vaccine Program (AAVP)








R UNODC EF ILO UNESCO WHO A WORLD BANK

Initiation of AAVP The Nairobi meeting June 2000

Two major outcomes:

 The Nairobi Declaration: An African Appeal for an HIV Vaccine.
The African AIDS Vaccine Strategy: An outline describing vision, goals, principles, milestones and activities framework.

AAVP was adopted by the African Heads of States at the HIV/AIDS, TB and Malaria summit in Abuja in April 2001 (Abuja declaration). Endorsed by ECOWAS, SADEC & NEPAD









The AAVP Vision and Mission

Vision: "An AIDS-Free Africa through an Effective Vaccine"

<u>Mission</u>: "The AAVP is a network of African HIV vaccine stakeholders, committed to HIV vaccine development for Africa, through research, advocacy, partnership, and contribution to capacity strengthening and policy development.







Objectives of the AAVP

- To develop advocacy strategies & communication tools on HIV vaccines
- To network people and institutions on HIV vaccines
- To promote the development of appropriate candidate vaccines for Africa
- To facilitate the preparation for clinical trials through capacity building
- To develop plans for future access in Africa







The Reasons for the Development of the New AAVP Strategic Plan

- The AAVP has been successful in a number of areas
- There is a changed global environment
- Support from stakeholders for continued activities and changes
- Great opportunity to take a leadership role
- Need for structural and functional changes







The AAVP Identity

- African Network located in Africa and led by African leaders representing various communities involved in HIV vaccine R&D
- A central platform ensuring adequate support, global representation and equal partnership role of African communities in the global HIV vaccine R&D efforts
- Contributes to creation of a supportive normative environment and meaningful capacity in African countries for the conduct of all phases oh HIV vaccine trials in Africa at the highest scientific and ethical standards
- Diversified structure of collaborating institutions across the continent with extensive expertise in various areas of work and their ability to spead this expertise base to other relevant partners







The AAVP Principles for Partnerships and Collaboration


- The AAVP central role is to be a partnership-based network with external and internal stakeholders, coherent with the goals of the Global HIV Vaccine Enterprise
- Involvement of all relevant stakeholders and development agencies, including the non-HIV, poverty diseases targeted programmes, based on open collaboration and complementarity
- Sharing its resources, capacities, experiences and information
- Alignment with multiple global initiatives for funding opportunities







The Former AAVP Structure



AAVP Structure: Principles for the proposed new structure


- 1. Take into account the recently conducted external review.
- 2. Reflect the outcomes of the consultation process (internal and external) conducted as part of this strategy development process.
- 3. Structured on the basis of what is thought to give the greatest operational and functional efficiency and professional approach.
- 4. The type of proposed AAVP work should influence the structure.
- 5. The magnitude of the planned efforts should influence the structure.
- 6. Ensure transparency and accountability.
- 7. Take into account the realities of the new funding environment.







The AAVP Structure (5 year strategic plan 2006-2011)



* National strategic planning managed by AAVP secretariat as one of the activities







AAVP Framework for it's 5 year Strategic Plan (2006-2011)

AAVP Work Areas	AAV	P Sti	rateg	ic Dir	rectio	ns
Country-based strategic planning	Cap		P	Co		
Biomedical research	Capacity	A	Policy I	Community	Ne	
Communication & media	Stren	Advocacy	Development		Networking	
Regulatory issues	Strengthening	су	opme	Involment	ing	
Ethics, law and human rights	ling		nt	ent		
World Health Organization	AYP				JAIDS	UNHCE UNODC UNICEF ILD WIFF UNESCO UNOP WHO UNIPA WORLD BAI

African AIDS Vaccine Program

AAVP Collaborating Centers: Progress Report

Biomedical research	Professor Souleymane MBoup Senegal
Communication & media	ACE Communication and Media, Kenya
Regulatory issues	
Ethics, law and human rights	Dr. Doug Wassernaar S. Africa







AAVP Biomedical Collaborating Centre for HIV/AIDS vaccine research and development, and clinical trials in the African region







AAVP BMCC Objectives (1)

To evaluate and identify needs and priorities

- assessment which will be done using a questionnaire

-Collection of information from partners

-Exchanges of experiences from experts, countries conducting trials and consensus workshop.







AAVP BMCC Objectives (2)

To initiate and develop networking and exchange of expertise

-between countries, institutions, initiatives and partners

-strengthening of existing networks such as the AARN

- collaboration with other institutions.







AAVP BMCC Objectives (3)

Strengthen capacity building :

-workshops, short and long term training focusing on laboratory techniques

 current technologies and approaches to standardise measurements of vaccine-induced immune responses,
immune correlates of HIV infection and pathogenesis,

monitor viral strains circulating in populations in Africa
sample preparation and tracking,

-repository management,

- QA/QC etc.







AAVP BMCC Objectives (4)

To implement a database on clinical trials in the region :

- updated list of all researchers and stakeholders on HIV/AIDS vaccine research and development on the continent
- available techniques and tools needed to monitor immune and virological responses
- physiological normal values for African population
- updated molecular epidemiology of HIV strains circulating in the region







AAVP BMCC

- Reinforce partnership with institutions, initiatives and universities involved in the area of HIV/AIDS vaccine.
- Virtual centre with the co-ordinating centre in Senegal and affiliated centres in Uganda and South Africa.









National AIDS Vaccine Plans


January	2001	Nigeria	
July	2001	Tanzania	
October	2001	Zambia	
September	2002	Cote D'Ivoire	
October	2002	Ethiopia	
November	2002	Cameroon	
September	2003	Uganda <mark>(update)</mark>	
March	2006	Uganda <mark>(update)</mark>	
July	2004	Kenya	
September	2004	Tanzania (<mark>update</mark>)	
December	2004	Botswana	
March	2005	Kenya	







Developing the Nigerian National Vaccine Plan



Developed under the coordination of National Action Committee on AIDS (NACA)



Coumba Tourec from WHO/UNAIDS facilitating the workshop in Abuja to develop Nigerian HIV vaccine Plan. *April 2000*





AAVP Forums

A Highly visibility meeting bringing together all partners, including African and international scientists, research agencies and donors

June 2002: The First AAVP Forum was launched in Cape Town, South Africa <u>Major recommendation</u>: Develop strategies and plans to support the on-going efforts to implement multiple HIV vaccine trial sites in Africa.

June 2003: 2nd forum in Addis Ababa, Ethiopia <u>Major recommendation</u>: Need the development of ethical, legal and regulatory frameworks in support of the development of HIV vaccine trial sites

October 2005: 3rd forum in Yaoundé, Cameroon <u>Major recommendation</u>: **YAOUNDE STATEMENT** - Need to better define Africa's role and contribution to the global efforts for the development of safe, effective and affordable HIV vaccines for African countries,.

November 28th -30th 2007: 4th forum in Abuja, Nigeria <u>Major recommendation</u>: ??







Potential Areas of Collaboration

- Implementation of National Vaccine Plans
- Work together on advocacy, policy and community issues
- Human Resources Capacity building Training fellowships
- Support capacity building (GCP, regulatory, ethics, scientific)
- Site development including support of other trials e.g. malaria or TB which could have benefit to HIV vaccine trials
- Support targeted research via institutional and regional collaboration (new AAVP collaborating centers): http://www.who.int/vaccine_research/diseases/hiv/aavp/aavp _full_applications/en/index.html









- CIDA Canada
- SIDA/SAREC Sweden
- WHO/UNAIDS
- Netherlands
- IAVI
- CDC, NIH, ANRS, DoD, SAAVI (Co-sponsor specific activities)







Acknowledgement

Steering Committee Members:

- Pontiano Kaleebu (Uganda)- chair
- Alash'le Abimiku (Nigeria/USA) vice-chair
- John Nkengasong (Cameron/USA)
- Dawit Wolday (Ethiopia)
- Shenaaz El Halabi (Botswana)
- Sinata Koulla-Shiro (Cameroun)
- Coumba Toure Kane (Senegal)

WHO AAVP Secretariat Marie-Paule Kieny Saladin Osmanov Coumba Touré Guy Michel Gershy Damet Raymond Hutubessy

AIDS Vaccine Family and AAVP Sponsors





